SCHEMBL3377174

SCHEMBL3377174

CCOC(=O)c1ccc(CNS(=O)(=O)Cc2ccc(-c3ccc(OC(C)C)cc3)c(C)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.42
ACACA Q13085 2/20 0.42
MAPT P10636 6/20 0.41
TP53 P04637 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC26A6 Q9BXS9 1/20 0.39
ALDH1A1 P00352 2/20 0.39
NR1H4 Q96RI1 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HPGD P15428 1/20 0.39
STS P08842 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3376139 0.89 KMT2A (0.47) ACACBACACATP53KMT2ANR1H4
SCHEMBL982169 0.73 CA12 (0.59) MAPTTP53SMN1; SMN2KMT2AALDH1A1
SCHEMBL28654333 0.71 CA12 (0.46) MAPTSMN1; SMN2L3MBTL1KMT2AALDH1A1
SCHEMBL4808100 0.68 TDP1 (0.53) MAPTL3MBTL1NPC1RAB9ACA12
SCHEMBL1337526 0.68 ACACB (0.60) ACACBACACAKMT2AALDH1A1HPGD
SCHEMBL6481796 0.68 GRIA4 (0.50) MAPTKMT2AALDH1A1HPGDSTS
SCHEMBL6481802 0.68 HPGD (0.46) MAPTSMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL28661980 0.68 HSD17B1 (0.65) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL3376266 0.67 FEN1 (0.42) KMT2A
SCHEMBL4119044 0.67 MAPT (0.66) MAPTTP53SMN1; SMN2L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 ACACB 1289/4885ACACA 970/4885MAPT 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.